Business
Omnicell Reports Second Quarter 2020 Results
GAAP revenues of $199.6 million and net loss per diluted share of $0.10 Non-GAAP revenues $199.6 million and net income per diluted share of $0.37 Omnicell’s
About this update from Omnicell, Inc.
[{"type":"text","content":"\nGAAP revenues of $199.6 million and net loss per diluted share of $0.10\n\n\nNon-GAAP revenues $199.6 million and net income per diluted share of $0.37\n\n\nOmnicell’s Response to Coronavirus (COVID-19)\n\n MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--\nOmnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2020.\n\n\nGAAP Results\n\n\nGAAP revenues for the second quarter of 2020 were $199.6 million, down $17.8 million, or 8.2% from the second quarter of 2019. GAAP revenues for the six months ended June 30, 2020 were $429.3 million, up $9.4 million, or 2.2% from the six months ended June 30, 2019.\n\n\nSecond quarter 2020 GAAP net loss was $4.3 million, or $0.10 per diluted share. This compares to GAAP net income of $16.0 million, or $0.37 per diluted share, for the second quarter of 2019.\n\n\nGAAP net income for the six months ended June 30, 2020 was $7.0 million, or $0.16 per diluted share. This compares to GAAP net income of $19.3 million, or $0.45 per diluted share, for the six months ended June 30, 2019.\n\n\nNon-GAAP Results\n\n\nNon-GAAP revenues for the second quarter of 2020 were $199.6 million, down $17.8 million, or 8.2%, from the second quarter of 2019. Non-GAAP revenues for the six months ended June 30, 2020 were $429.3 million, up $9.4 million, or 2.2%, from the six months ended June 30, 2019.\n\n\nNon-GAAP net income for the second quarter of 2020 was $15.9 million, or $0.37 per diluted share. This compares to non-GAAP net income of $28.7 million, or $0.67 per diluted share, for the second quarter of 2019.\n\n\nNon-GAAP net income for the six months ended June 30, 2020 was $44.8 million, or $1.03 per diluted share. This compares to non-GAAP net income of $54.5 million, or $1.28 per diluted share, for the six months ended June 30, 2019.\n\n\nNon-GAAP net income for each period excludes, when applicable, the effect of share-based compensation expense, amortization expense of acquired intangible assets, acquisition-related expenses, restructuring and severance-related expenses, tax restructuring benefits and expenses, and amortization of debt issuance costs.\n\n\nOmnicell’s Response to Coronavirus (COVID-19)\n\n\nKeeping in mind our role in the healthcare industry, we are...